In surprise decision, US approves muscular dystrophy drug

In surprise decision, US approves muscular dystrophy drug

A logo sign outside of the headquarters of Sarepta Therapeutics, Inc, in Cambridge, Massachusetts on February 21, 2018. Kristoffer Tripplaar | AP U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago. The ruling marks the … Read more…